Lyell Immunopharma Announces Participation in Upcoming Investor Conferences
Rhea-AI Summary
Lyell Immunopharma (Nasdaq: LYEL), a clinical-stage company focused on developing next-generation CAR T-cell therapies for cancer patients, has announced its participation in two upcoming investor conferences. The company's senior management team will present at:
- The H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on February 25th at 2:30 pm Eastern Time
- The TD Cowen's 45th Annual Health Care Conference on March 3rd at 11:50 am Eastern Time
Interested parties can access live webcasts of the presentations through the Investors section of Lyell's website (www.lyell.com). Replay options will be available on the company's website following the live presentations.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, LYEL gained 1.54%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced today that members of its senior management team will present and participate the following upcoming investor conferences:
- H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on February 25th at 2:30 pm Eastern Time
- TD Cowen's 45th Annual Health Care Conference on March 3rd at 11:50 am Eastern Time
A live webcast of the presentation can be accessed through the Investors section of the Company's website at www.lyell.com. Following the live presentation, a replay of the webcast will be available on the Company's website.
About Lyell
Lyell is a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. To realize the potential of cell therapy for cancer, Lyell utilizes a suite of technologies to endow CAR T cells with attributes needed to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical responses, including the ability to resist exhaustion, maintain qualities of durable stemness and function in the hostile tumor microenvironment. Lyell is based in South San Francisco, California with facilities in West Hills, California and Seattle and Bothell, Washington. To learn more, please visit www.lyell.com.
Contact:
Ellen Rose
Senior Vice President, Communications and Investor Relations
erose@lyell.com
FAQ
When is Lyell Immunopharma (LYEL) presenting at the H.C. Wainwright Cell Therapy Conference?
What time is LYEL's presentation at the TD Cowen Healthcare Conference?
How can investors access Lyell Immunopharma's (LYEL) upcoming conference presentations?
What type of therapies is Lyell Immunopharma (LYEL) developing?
